Hypoglycemic effect enhancer

Inventors

Isa, Yasuhiro • Shimakawa, Masaki • Ohno, Hiroshi • Yamamura, Hideki

Assignees

Biofermin Pharmaceutical Co Ltd

Abstract

A hypoglycemic effect enhancer for enhancing the activity of an α-glucosidase inhibitor, the enhancer comprising at least one kind of bacteria selected from the group consisting of bifidobacteria, lactic acid bacteria, saccharifying bacteria, and butyric acid bacteria.

Core Innovation

The invention relates to a hypoglycemic effect enhancer that synergistically enhances the hypoglycemic activity of an α-glucosidase inhibitor by administering at least one bacterial type selected from bifidobacteria, lactic acid bacteria, saccharifying bacteria, and butyric acid bacteria. The α-glucosidase inhibitor includes voglibose and voglibose derivatives, and the document also describes inhibitors such as acarbose and miglitol or miglitol-like scaffolds.

The problem being solved is that single-agent administration is not sufficient to achieve the desired hypoglycemic effect, whereas combination administration significantly lowers fasting glucose and improves glucose tolerance as assessed by glucose-load (OGTT) results. The document reports reduced AUC and improved glucose tolerance in diabetic model mice when the bacterial combination is administered together with the α-glucosidase inhibitor.

The disclosed hypoglycemic effect enhancer includes enhancer compositions, pharmaceutical compositions, and food or drink compositions. The document also describes preparations of dried bacterial cells, including spray-drying using a 4-channel nozzle, to maintain a high viable cell ratio.

Claims Coverage

The provided independent claims are directed to methods that enhance or promote hypoglycemic activity related to voglibose using specific combinations of bacterial types. Across the independent claims, the inventive features focus on combined administration of lactic acid bacteria and saccharifying bacteria or bifidobacteria with voglibose.

Across the independent claims, the core claimed concept is combined administration of lactic acid bacteria together with saccharifying bacteria or bifidobacteria and voglibose, where the stated outcome is enhancement of voglibose hypoglycemic activity, enhancement of bacterial hypoglycemic activity, or promotion of expression of voglibose hypoglycemic activity.

Stated Advantages

Documented Applications